Which tumour biomarker findings define the adult colorectal cancer indication for nivolumab (OPDIVO) with ipilimumab?

Nivolumab (OPDIVO) with ipilimumab is indicated for adults with mismatch repair deficient or microsatellite instability-high colorectal cancer, as first-line treatment for unresectable or metastatic disease, or for metastatic disease after prior fluoropyrimidine-based combination chemotherapy.